Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials.

Cancers (Basel) · 2024 · PMC11393907 · PMID 39272879

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A trial combining gefitinib and cediranib, targeting EGFR and VEGFR, showed a trend towards an improved response rate in recurrent GBM patients in a phase II trial [ 61 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.